Examination of the Application Support Layer of CCSDS SOIS Using SpaceWire Communication Stack and Low-Code User Application

As a SmallSat grows, there is an increasing need for high-speed and high-functioning sub-networks, such as SpaceWire, to connect equipment to the OBC and store large amounts of optical image data. SpaceWire has the ability for time-sensitive delivery, fast communication, and flexible network topology construction. JAXA/ISAS has developed SIB2, a low-code user application that designs telemetry commands based on a database stored on the satellite. SIB2 has a code generation function called SIB2Generator, which outputs code that performs the behavior of telemetry commands during sender/receiver and is used as a template for user applications. On the other hand, the Application Support Layer of CCSDS SOIS is positioned between sub-networks and user applications. And then, service types are defined in the Application Support Layer, but no concrete implementation interface is specified. Therefore, we have implemented an examination of the Command and Data Acquisition Services layer using SIB2 and the SpaceWire communication stack. In the executed study, we adopted the SpaceWire RMAP Library, a class library that makes SpaceWire communication. Using this library, we have designed and developed the Application Support Layer, integrating the SpaceWire application stack based on the SIB2 database design and the user application code generated by SIB2Generator

Cost Analysis of Screening for IgA Nephropathy Using Novel Biomarkers

[Objectives] IgA nephropathy (IgAN) is the most common primary chronic glomerulonephritis and a major cause of end-stage kidney disease worldwide. Novel biomarkers, including the aberrantly glycosylated IgA1 and glycan-specific antibodies, could be useful in the diagnosis of IgAN. The aim of this study was to assess the cost analysis of IgAN screening using novel biomarkers in addition to the conventional screening compared with conventional screening alone. [Methods] To estimate the medical expense of each strategy related to renal disease for 40 years, we developed an analytical decision model. The decision tree started at “40 years of age with first-time hematuria.” It simulated 2 clinical strategies: IgAN screening using the novel biomarkers (group N) and conventional screening (group C). The analysis results were presented as medical expenses from a societal perspective. Discounting was not conducted. [Results] The expected medical expense per person for 40 years was ¥31.2 million (~$291 000) in group N and ¥33.4 million (~$312 000) in group C; hence, expense in group N was lower by ¥2.2 million (~$21 000). In group N, the expected value of IgAN increased by 5.67% points (N 48.44%, C 42.77%) and that of dialysis introduction decreased by 0.85% points (N 19.06%, C 19.91%). In the sensitivity analysis, expenses could be reduced in almost all cases except when renal biopsy using conventional screening was performed at the rate of 73% or higher. [Conclusion] Screening for IgAN using novel biomarkers would reduce renal disease–related expenses

Discovery of a new pulsating X-ray source with a 1549.1-s period, AX J183220-0840

A new pulsating X-ray source, AX J183220-0840, with a 1549.1-s period was discovered at R.A.= 18h32m20s and Dec.=-8d40'30'' (J2000, uncertainty=0.6degree) during an ASCA observation on the Galactic plane. The source was observed two times, in 1997 and in 1999. A phase-averaged X-ray flux of 1.1E-11 ergs cm-2 s-1 and pulsation period of 1549.1+/-0.4 s were consistently obtained from these two observations. The X-ray spectrum was represented by a flat absorbed power-law with a photon-index of =~0.8 and an absorption column density of =~1.3E22 cm-2. Also, a signature of iron K-shell line emission with a centroid of 6.7 keV and an equivalent width of approximately 450 eV was detected. From the pulsation period and the iron-line feature, AX J183220-0840 is likely to be a magnetic white dwarf binary with a complexly absorbed thermal spectrum with a temperature of about 10 keV.Comment: 13 pages, 4 figures, accepted for publication in ApJ Letter

Plasma S100A12 Levels and Peripheral Arterial Disease in End-Stage Renal Disease

Background: S100A12 is an endogenous ligand of the receptor for advanced glycation end products (RAGE). Plasma S100A12 levels are high in end-stage renal disease (ESRD) patients undergoing maintenance hemodialysis (HD). Peripheral arterial disease (PAD) is common in HD patients and is associated with increased cardiovascular morbidity and mortality rates in this population. To date, however, no study has specifically assessed the relationship between plasma S100A12 and PAD in HD patients. Methods: We conducted a cross-sectional study of 152 HD patients in our affiliated hospital. We investigated PAD history and patient characteristics and quantified plasma S100A12 levels in all participants. Results: HD patients with PAD (n = 26; 21.9 [13.6–33.4] ng/ml) showed significantly higher plasma S100A12 levels than HD patients without PAD (n = 126; 11.8 [7.5–17.6]ng/ml; p Conclusion: These results suggest that plasma S100A12 levels are strongly associated with PAD prevalence in ESRD patients undergoing HD